. "erectile dysfunction; PDE-5 inhibitors; tadalafil"@en . . "Daily therapy of erectile dysfunction \u2013 who is it for, what are the risks?"@en . "RIV/00216224:14110/11:00054990" . "1213-1768" . "CZ - \u010Cesk\u00E1 republika" . . "\u0160r\u00E1mkov\u00E1, Ta\u0165\u00E1na" . "Denn\u00ED terapie erektiln\u00ED dysfunkce \u2013 pro koho a s jak\u00FDmi riziky?"@cs . "RIV/00216224:14110/11:00054990!RIV12-MSM-14110___" . . "3"^^ . "[8934DAF8B756]" . . "1"^^ . "Erectile dysfunction (ED) is defined as an inability to achieve and maintain an erection sufficient for satisfactory sexual intercourse. Phosfodiesterase type 5 (PDE5) inhibitors are first line oral medication for erectile dysfunction (ED). Tadalafil 5 mg was well tolerated and effective in clinical studies, it was alternative to the current on-demand dosing of tadalafil for men with ED. Patients and their sexual partners preferred once daily administration, mainly because longer efficacy, safety allowing a more spontaneous sexual life."@en . "1"^^ . "Erektiln\u00ED dysfunkce (ED) je definov\u00E1na jako neschopnost dos\u00E1hnout a udr\u017Eet ztopo\u0159en\u00ED dostate\u010Dn\u00E9 k realizaci uspokojiv\u00E9ho sexu\u00E1ln\u00EDho styku. Inhibitory fosfodiester\u00E1zy 5 (I-PDE5) jsou prvn\u00EDm krokem v l\u00E9\u010Db\u011B erektiln\u00ED dysfunkce. N\u00EDzkod\u00E1vkovan\u00FD tadalafil byl v klinick\u00FDch studi\u00EDch dob\u0159e tolerovan\u00FD a \u00FA\u010Dinn\u00FD, p\u0159edstavoval alternativu k b\u011B\u017En\u011B u\u017E\u00EDvan\u00E9mu tadalafilu jednor\u00E1zov\u011B p\u0159ed stykem. Pacienti i jejich sexu\u00E1ln\u00ED partnerky preferovali denn\u00ED u\u017Eit\u00ED tadalafilu, oce\u0148ovali p\u0159edev\u0161\u00EDm vysokou \u00FA\u010Dinnost, bezpe\u010Dnost a mo\u017Enost spont\u00E1nn\u00EDho sexu\u00E1ln\u00EDho \u017Eivota."@cs . . . "Urologie pro praxi" . "193315" . "V" . . "14110" . "Daily therapy of erectile dysfunction \u2013 who is it for, what are the risks?"@en . . "Denn\u00ED terapie erektiln\u00ED dysfunkce \u2013 pro koho a s jak\u00FDmi riziky?" . "Denn\u00ED terapie erektiln\u00ED dysfunkce \u2013 pro koho a s jak\u00FDmi riziky?" . . "12" . . . "Denn\u00ED terapie erektiln\u00ED dysfunkce \u2013 pro koho a s jak\u00FDmi riziky?"@cs . "Erektiln\u00ED dysfunkce (ED) je definov\u00E1na jako neschopnost dos\u00E1hnout a udr\u017Eet ztopo\u0159en\u00ED dostate\u010Dn\u00E9 k realizaci uspokojiv\u00E9ho sexu\u00E1ln\u00EDho styku. Inhibitory fosfodiester\u00E1zy 5 (I-PDE5) jsou prvn\u00EDm krokem v l\u00E9\u010Db\u011B erektiln\u00ED dysfunkce. N\u00EDzkod\u00E1vkovan\u00FD tadalafil byl v klinick\u00FDch studi\u00EDch dob\u0159e tolerovan\u00FD a \u00FA\u010Dinn\u00FD, p\u0159edstavoval alternativu k b\u011B\u017En\u011B u\u017E\u00EDvan\u00E9mu tadalafilu jednor\u00E1zov\u011B p\u0159ed stykem. Pacienti i jejich sexu\u00E1ln\u00ED partnerky preferovali denn\u00ED u\u017Eit\u00ED tadalafilu, oce\u0148ovali p\u0159edev\u0161\u00EDm vysokou \u00FA\u010Dinnost, bezpe\u010Dnost a mo\u017Enost spont\u00E1nn\u00EDho sexu\u00E1ln\u00EDho \u017Eivota." . . . "4" . .